Activating mutations in one of the JAK2-utilizing receptors in the myeloid lineage, the thrombopoietin receptor (TpoR W515L or TpoR W515K), account for about 5–8% of the JAK2 V617F-negative ET and PMF cases 7,8. Here, MPL is linked to essential thrombocythemia.